Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Idioma
Tipo del documento
Intervalo de año de publicación
1.
Artículo en Ruso | MEDLINE | ID: mdl-1950285

RESUMEN

The isolation and properties of endotoxin protein, or lipid A-associated protein (LAP), from Shigella sonnei were described earlier (Zh. mikrobiol. epidemiol. immunobiol., 1991, No. 4, pp. 11-17, and No. 7). In this report the data on its protective activity are presented. In experiments on mice one nanogram of LAP injected i. v. protected 50% of the animals against i. p. challenge with 40 LD50 of virulent S. sonnei. Guinea pigs injected s. c. with 10 micrograms of LAP were protected against local (keratoconjunctival) challenge with S. sonnei, the efficiency of immunization being 58%. LAP preparations containing no detectable amounts of O-antigen (less than 0.003%) were found to have a protective effect. Hyperimmune anti-LAP rabbit serum prevented local infection when incubated with S. sonnei challenge inoculum before injection into guinea pigs. Both active and passive protection induced by LAP was specific since no effect was observed in animals challenged with Shigella flexneri. In the homologous system the protective effect of anti-LAP serum was abolished by the addition of protein-free LPS. These results are compatible with the hypothesis that the protective activity of LAP depends on the presence of minute amounts of O-antigen whose immunogenic effect is greatly amplified by the protein component of the natural endotoxin complex.


Asunto(s)
Proteínas Bacterianas/inmunología , Endotoxinas/inmunología , Lípido A/inmunología , Shigella sonnei , Animales , Proteínas Bacterianas/aislamiento & purificación , Evaluación Preclínica de Medicamentos , Disentería Bacilar/prevención & control , Endotoxinas/aislamiento & purificación , Cobayas , Inmunización Pasiva/métodos , Queratoconjuntivitis/prevención & control , Lípido A/aislamiento & purificación , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Shigella flexneri , Vacunación/métodos
2.
Zh Mikrobiol Epidemiol Immunobiol ; (4): 47-50, 1991 Apr.
Artículo en Ruso | MEDLINE | ID: mdl-1882607

RESUMEN

Ribosomal preparations from Shigella flexneri and Shigella sonnei, introduced parenterally into mice, enhance their resistance to infection with the causative agents of typhoid fever and staphylococci. This effect is considerably less pronounced than that produced by the preparation of homologous lipopolysaccharide isolated by Boivin's method. After the administration of ribosomes nonspecific resistance to bacterial infective agents lasts for a short time. Ribosomal preparations do not enhance the resistance of mice to the lethal action of endotoxin.


Asunto(s)
Vacunas Bacterianas/inmunología , Ribosomas/inmunología , Salmonelosis Animal/prevención & control , Salmonella typhi , Shigella flexneri/inmunología , Shigella sonnei/inmunología , Choque Séptico/prevención & control , Infecciones Estafilocócicas/prevención & control , Animales , Vacunas Bacterianas/aislamiento & purificación , Evaluación Preclínica de Medicamentos , Inmunidad Innata/efectos de los fármacos , Inmunidad Innata/inmunología , Lipopolisacáridos/inmunología , Lipopolisacáridos/aislamiento & purificación , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Salmonelosis Animal/inmunología , Salmonella typhi/patogenicidad , Choque Séptico/inmunología , Infecciones Estafilocócicas/inmunología , Staphylococcus aureus/patogenicidad , Virulencia
3.
Antibiot Khimioter ; 33(8): 612-4, 1988 Aug.
Artículo en Ruso | MEDLINE | ID: mdl-2848468

RESUMEN

Therapeutic efficacy of ristomycin in visceral actinomycosis, a severe disease difficult for diagnosis requiring long-term complex therapy was studied on 24 rabbits. The animals were divided into 4 groups. A model of thoracal actinomycosis was developed. 7 rabbits were treated with ristomycin. The other 7 rabbits were treated with ristomycin in combination with actinolysate, a specific immune preparation. 5 rabbits were treated with actinolysate alone and the other 5 rabbits received no treatment. alone and especially in combination with actinolysate was an efficient therapeutic agent for treatment of severe visceral actinomycosis. This allowed to recommend ristomycin for clinical trials in treatment of the disease.


Asunto(s)
Infecciones por Actinomycetales/tratamiento farmacológico , Enfermedades Pulmonares/tratamiento farmacológico , Ristocetina/uso terapéutico , Infecciones por Actinomycetales/mortalidad , Infecciones por Actinomycetales/patología , Adyuvantes Inmunológicos/uso terapéutico , Animales , Bacteriocinas/uso terapéutico , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Pulmón/patología , Enfermedades Pulmonares/mortalidad , Enfermedades Pulmonares/patología , Conejos , Streptomyces , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA